Laboratory Corp of America Holdings (LH)

HEALTH CARE: HEALTH CARE SERVICES
SIC: SERVICES-MEDICAL LABORATORIES

358 S MAIN ST BURLINGTON, NC 27215

Laboratory Corporation of America is a holding company. Co. provides clinical laboratory tests used in routine testing, patient diagnosis, and in the monitoring and treatment of disease. Co. also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, identity, forensics, infectious disease, oncology and occupational testing. As of Dec 31 2009, Co. had a network of 38 primary laboratories and about 1,500 patient service centers along with a network of branches and STAT laboratories, which are laboratories that have the ability to perform certain routine tests and report the results to the physician immediately.

Data based on most recent fiscal year report
Market Cap16.641 Billion Shares Outstanding101.8 Million Avg Volume1.102 Million
1-Yr BETA vs S&P TR Current Ratio1.31 Quick Ratio1.2
View SEC Filings from LH instead.
Q2 2019 All Institutions Hedge Funds 1
To trade LH now:
Filers who had this stock in their top 10: 15 4 (0.41%)
13F Filers holding this stock: 715 65 (6.71%)
Aggregate 13F shares on 06/30/2019: 88.002 Million 10.433 Million
Aggregate 13F shares on 03/31/2019: 90.238 Million 10.402 Million
Percent change: -2.48% 0.30%
Funds creating new positions: 72 13
Funds Adding to an existing position: 235 19
Funds closing out their position: 68 15
Funds reducing their position: 285 31
Heat Map Ranking for 06/30/2019 52
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding LH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

32.8 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

2.6 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KONG GARHENG

  • Director
0 2019-11-07 1

WILLIAMS R SANDERS

  • Director
5,413 2019-11-06 4

CAVENEY BRIAN J EVP, PRESIDENT OF DIAGNOSTICS

  • Officer
0 2019-11-05 2

SCHROEDER MARK S EVP, PRESIDENT-DIAGNOSTICS LAB

  • Officer
179 2019-11-05 2

ANDERSON KERRII B

  • Director
0 2019-11-03 3

SCHECHTER ADAM H PRESIDENT & CEO

  • Officer
  • Director
0 2019-11-01 2

EISENBERG GLENN A

  • Director
3,000 2019-11-01 7

KIRCHGRABER PAUL R CEO, COVANCE DRUG DEVELOPMENT

  • Officer
4,407 2019-11-01 2

KING DAVID P PRESIDENT & CEO

  • Officer
  • Director
325,475 2019-10-28 5

SELTZ JUDITH C CHIEF HUMAN RESOURCES OFFICER

  • Officer
0 2019-10-15 1

HAYES WILLIAM B

  • Director
0 2019-10-14 0

UTHGENANNT LISA J CHIEF HUMAN RESOURCES OFFICER

  • Officer
4,660 2019-09-04 6

BERBERIAN LANCE SVP, CHIEF INFORMATION OFFICER

  • Officer
6,097 2019-08-30 5

MITTELSTAEDT ROBERT E JR

  • Director
209,525 2019-08-14 3

HARDISON DON M

  • Director
12,500 2019-08-14 0

LANE WENDY E

  • Director
7,353 2019-08-13 0

COLES N ANTHONY

  • Director
1,296 2019-07-31 0

VAN DER VAART SANDRA D SVP, GLOBAL GENERAL COUNSEL

  • Officer
2,328 2019-07-08 3

NEUPERT PETER M

  • Director
0 2019-06-26 1

WALTON ANDREW SCOTT

  • Director
0 2019-06-18 0

PARHAM RICHELLE P

  • Director
5,702 2019-06-11 1

KELLER DEBORAH L

4,881 2019-05-07 0

LAI GOLDMAN MYLA

12,943 2019-05-07 0

FONSECA LIDIA

  • Director
28,772 2019-05-01 0

RATLIFF JOHN D CEO, COVANCE DRUG DEVELOPMENT

  • Officer
17,061 2019-04-03 4

DODSON EDWARD T PRINCIPAL ACCOUNTING OFFICER

  • Officer
13,663 2019-04-01 4

WILKINSON PETER J SVP, CHIEF ACCOUNTING OFFICER

  • Officer
0 2019-04-01 1

HERRING JOSEPH L

  • Director
12,343 2019-03-05 0

EBERTS F SAMUEL III CHIEF LEGAL OFFICER, SECRETARY

  • Officer
28,823 2019-02-12 3

BELINGARD JEAN-LUC

  • Director
34,013 2019-02-12 2

GILLILAND DWIGHT GARY

  • Director
4,539 2019-02-12 1

MAC MAHON THOMAS P

  • Director
0 2018-12-20 0

GARY M. HUFF CEO, LABCORP DIAGNOSTICS

  • Officer
1,850 2018-09-04 0

HAAS WILLIAM

  • Director
0 2016-09-07 0

MILLER BENJAMIN R

  • Director
0 2016-09-07 0

BOYLE JAMES T. JR. EVP,CEO OF LABCORP DIAGNOSTICS

  • Officer
23,454 2016-03-30 0

BRECHER MARK E CMO, LABCORP DIAGNOSTICS

  • Officer
5,511 2015-03-30 0

RUBENSTEIN ARTHUR H

  • Director
11,772 2014-05-08 0

WEIKEL M KEITH

  • Director
13,958 2014-05-07 0

CONRAD ANDREW J

  • Director
No longer subject to file 2013-11-01 0

SMITH BRADFORD T

  • Director
16,030 2009-02-20 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

2019-11-05 A 6,030 a 15,377 0.00 direct

SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

2019-11-05 A 6,030 a 7,644 0.00 direct

SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

2019-11-01 A 24,800 a 24,800 0.00 direct

KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

2019-11-01 A 6,020 a 9,854 0.00 direct

SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

2019-11-01 A 6,020 a 7,247 0.00 direct

SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

2019-11-01 A 65,100 a 65,100 0.00 direct

EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

2019-11-01 A 30,080 a 35,454 0.00 direct

KING DAVID P - Director - Officer PRESIDENT & CEO

2019-10-28 S 12,352 $166.21 d 305,933 325,475.39 direct yes

KING DAVID P - Director - Officer PRESIDENT & CEO

2019-10-28 S 10,391 $165.32 d 318,285 325,475.39 direct yes

KING DAVID P - Director - Officer PRESIDENT & CEO

2019-10-28 S 7,434 $164.16 d 328,676 325,475.39 direct yes

ANDERSON KERRII B - Director

2019-09-23 M 2,600 $98.49 a 20,533 19,133.00 direct yes

ANDERSON KERRII B - Director

2019-09-23 M 2,600 d 0 19,133.00 direct

ANDERSON KERRII B - Director

2019-09-23 S 2,600 $171.85 d 17,933 19,133.00 direct yes
Click here to report any possible errors with this stock listing.

Elevate your investments